What is Exagen Inc.'s remainder of fiscal year 2024?

Exagen Inc. (XGN) reported remainder of fiscal year 2024 of $2.78M in Q1 2026.

How has Exagen Inc.'s remainder of fiscal year 2024 changed year-over-year?

Exagen Inc.'s remainder of fiscal year 2024 increased by 54.2% year-over-year, from $1.8M to $2.78M.

Exagen Inc. XGN Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

Avalo TherapeuticsAVTX

——

CareDxCDNA

——

Bio-Rad LaboratoriesBIO

——

RevvityRVTY

——

Idexx LaboratoriesIDXX

——

Agilent TechnologiesA

——

Other financials

Income statement

See full

Revenue$17.3M+11.7%

Gross profit$10.2M+11.9%

Operating income-$3.4M-1.5%

Net income-$4.0M-5.7%

EPS (diluted)-$0.17+15.0%

Balance sheet

See full

Cash & equivalents$21.7M+90.6%

Total debt$27.1M+15.8%

Total equity$14.4M+125%

Total assets$52.0M+28.9%

Cash flow

See full

Operating cash flow-$10.4M+2.4%

CapEx$228.0K+102%

Free cash flow-$10.6M+1.3%

Valuation

See full

Market cap$112.34M-26.5%

Enterprise value$117.78M-20.3%

P/S1.6×-1.0×

Profitability

See full

Gross margin58.3%-1.0pp

Operating margin-20.6%-2.9pp

Net margin-29.5%+2.5pp

FCF margin-27.5%—

Returns & leverage

See full

Return on equity-193.6%+355pp

Debt / equity1.9×-1.8×

Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Exagen Inc.'s remainder of fiscal year 2024?: Exagen Inc. (XGN) reported remainder of fiscal year 2024 of $2.78M in Q1 2026.
How has Exagen Inc.'s remainder of fiscal year 2024 changed year-over-year?: Exagen Inc.'s remainder of fiscal year 2024 increased by 54.2% year-over-year, from $1.8M to $2.78M.